Time is Brain(stem) in Basilar Artery Occlusion
Stroke 43:3003-3006, Vergouwen, M.D.I.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated with Recombinant Tissue Plasminogen Activator
Stroke 43:2904-2909, Whiteley, W.N.,et al, 2012
Smartphone Teleradiology Application is Succesfully Incorporated Into a Telestroke Network Environment
Stroke 43:3098-3101, Demaerschalk, B.M.,et al, 2012
Factors Influencing In-Hospital Delay in Treatment with Intravenous Thrombolysis
Stroke 43:1578-1583, Mikulik, R.,et al, 2012
Primary Sjogren Syndrome
BMJ 344:e3821, Ramos-Casals, M.,et al, 2012
The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial
Lancet 379: 2320, IST-3 collaborative group, 2012
Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis
Lancet 379: 2364-2372, Wardlaw, J.M.,et al, 2012
Elderly Patients are at Higher Risk for Poor Outcomes after Intra-Arterial Therapy
Stroke 43:2356-2361, Chandra, R.V.,et al, 2012
A Pragmatic Approach Using Magnetic Resonance Imaging to Treat Ischemic Strokes of Unknown Onset Time in a Thrombolytic Trial
Stroke 43:2331-2335, Song, S.S.,et al, 2012
Early Administration of Aspirin in Patients Treated with Alteplase for Acute Ischaemic Stroke: A Randomised Controlled Trial
Lancet 380:731-737, Zinkstok, S.M.,et al, 2012
Solitaire Flow Restoration Device Versus the Merci Retriever in Patients with Acute Ischaemic Stroke (SWIFT): a Randomised, Parallel-Group, Non-Inferiority Trial
Lancet 380:1241-1249,1208, Saver, J.L.,et al, 2012
Trevo Versus Merci Retrievers for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2): A Randomised Trial
Lancet 380:1231-1240,1208, Nogueira, R.G.,et al, 2012
The Argatroban and Tissue-Type Plasminogen Activator Stroke Study
Stroke 43:770-775,623, Barreto,A.D.,et al, 2012
Does Helicopter Emergency Medical Service Transfer Offer Benefit to Patients with Stroke?
Stroke 43:878-880, Olson,M.D. and Rabinstein,A.A., 2012
The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012
Selecting Stroke Patients for Intra-Arterial Therapy
Neurol 78:755-761, Balucani,C. and Grotta,J.C., 2012
CNS Involvement at the Onset of Primary Hemophagocytic Lymphohistiocytosis
Neurol 78:1150-1156, Deiva,K.,et al, 2012
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
NEJM 366:1099-1107, Parsons,M.,et al, 2012
Bridging Therapy in Acute Ischemic Stroke
Stroke 43:1302-1308, Mazighi,M.,et al, 2012
Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis: The SEDAN Score
Ann Neurol 71:634-641, Strbian,D.,et al, 2012
Infarct Volume is a Pivotal Biomarker After Inter-Arterial Stroke Therapy
Stroke 43:1323-1330, Yoo,A.J.,et al, 2012
Infective Endocarditis at Autopsy
Medicine 91:152-164, Fernandez Guerrero,M.L.,et al, 2012
Central Nervous System Neuronal Surface Antibody Associated Syndromes: Review and Guidelines for Recognition
JNNP 83:638-645, Zuliani,L.,et al, 2012
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
Acute Stroke Imaging: What is Sufficient for Triage to Endovascular Therapies?
AJNR 33:790-792, Lev, M.H., 2012
Hashimoto Encephalopathy
Neurol 78:e134, Afshari, M.,et al, 2012
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012
The Diagnosis and Treatment of Limbic Encephalitis
Acta Neurol Scand 126:365-375, Asztely, F. & Kumliem, E., 2012
Spontaneous Regression of an Intracerebral Lymphoma (ghost tumor) in a Liver-Engrafted Patient
The Neurologist 17:218-221, Korner, S.,et al, 2011
Intravenous Thrombolysis in Nonagenarians With Ischemic Stroke
Stroke 42:1967-1970, Sarikaya, H.,et al, 2011
Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age
JNNP 82:712-717, Bhatnagar, P.,et al, 2011
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Subtherapeutic International Normalized Ratio in Warfarin-Treated Patients Increases the Risk for Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis
Stroke 42:2333-2335, Seet, R.C.S.,et al, 2011
Impact of Obesity on Stroke Outcome After Intravenous Thrombolysis
Stroke 42:2330-2332, Sarikaya, H.,et al, 2011
Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis
Neurol 77:341-348, Strbian, D.,et al, 2011
Advanced Brain Imaging Studies Should Be Performed in Patients With Suspected Stroke Presenting Within 4.5 Hours of Symptom Onset
Stroke 42-2666-2667,2670, Parsons, M.W., 2011
Advanced Brain Imaging Studies Should Not Be Performed in Patients With Suspected Stroke Presenting Within 4.5 Hours of Symptom Onset
Stroke 42:2668-2669,2670, Lyden, P.D., 2011
Safety and Functional Outcome of Thrombolysis in Dissection-Related Ischemic Stroke A Meta-Analysis of Individual Patient Data
Stroke 42:2515-2520, Zinkstok, S.M.,et al, 2011
Effects of Extending the Time Window of Thrombolysis to 4.5 Hours Observations in the Swedish Stroke Register (Riks-Stroke)
Stroke 42:2492-2497, Asplund, K.,et al, 2011
Progressive Multifocal Leukoencephalopathy in Transplant Recipients
Ann Neurol 70:305-322, Mateen, F.J.,et al, 2011
Autoimmune Limbic Encephalitis with GAD Antibodies
The Neurohospitalist 1:178-181, Finelli, P.F., 2011
Paraneoplastic and Autoimmune Encephalitis
UpToDate, June, Dalmau, J.,et al, 2011
Low-Dose Recombinant Tissue-Type Plasminogen Activator Enhances Clot Resolution in Brain Hemorrhage
Stroke 42:3009-3016,2999, Naff, N.,et al, 2011
The Cost-Effectiveness of Telestroke in the Treatment of Acute Ischemic Stroke
Neurol 77:1590-1598, Nelson, R.E.,et al, 2011
Percutaneous Vascular Interventions for Acute Ischemic Stroke
Stroke 42:e31-e32, ORourke,K.,et al, 2011
Stem Cell Transplantation for Ischemic Stroke
Stroke 42:e33, Boncoraglio,G.B.,et al, 2011
Tumefactive Demyelination, an Uncommon Form of Tacrolimus Neurotoxicity
Neurol 76:672-674, Kim,S.H.,et al, 2011
Association Between Stroke Center Hospitalization for Acute Ischemic Stroke and Mortality
JAMA 305:373-380, Xian,Y.,et al, 2011
Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator
Stroke 42:1041-1045, Vergouwen,M.D.I.,et al, 2011